Apart from Pfizer’s (PFE) product developments, a few of the recent pipeline and corporate developments follow.
The recent corporate developments reported are as follows:
- Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapy for treating rare diseases. The company had acquired a 22% stake in 1Q16, while it acquired the remaining equity in August 2016.
- Pfizer and Western Oncolytics announced a collaborative agreement to develop the oncolytic virus WO-12 for the treatment of cancer. According to the agreement, Pfizer has an option to acquire WO-12 after the completion of the Phase I trial.
- Pfizer acquired Anacor Pharmaceuticals on June 23, 2016. The acquisition will help strengthen the Inflammation and Immunology portfolio of Pfizer’s Innovative Pharmaceuticals segment.
The recent pipeline developments reported include:
- Merck’s (MRK) and Pfizer’s first pivotal phase II study for Avelumab showed positive response in the treatment of patients with Merkel cell carcinoma. The data was published in June 2016.
- In June 2016, Pfizer presented data from the Phase I trial for Utomilumab in combination with pembrolizumab for the treatment of patients with advanced solid tumors
- Pfizer announced positive results from second phase III studies of Xeljanx for the treatment of patients with psoriatic arthritis, on June 7, 2016.
- In June 2016, Merck and Pfizer announced two phase III studies for Ertugliflozin achieving the primary endpoints for the treatment of type II diabetes.
- Pfizer announced positive top line results from two phase III studies for Bococizumab. These studies include SPIRE-FH and SPIRE-HR.
To diversify the risk, investors can consider ETFs like the iShares US Healthcare ETF (IHE), which holds ~8.4% of its total investments in Pfizer. IHE also holds ~10% of its investments in Johnson and Johnson (JNJ), ~7.4% in Merck and Co. (MRK), and ~6.7% in Bristol-Myers Squibb (BMY).